INSIGHTS ON ENTERPRISE SOLUTIONS
-
![GettyImages-533937117-mrna-chemicals]( "Improving CD Media Titers With Nu-Tek Peptones")
Improving CD Media Titers With Nu-Tek PeptonesAdding 0.2% soy peptone to chemically defined media increases CHO IgG production by 30–60%. This animal-free supplementation enhances titers while maintaining high process control.
-
![GettyImages-2189362114-recombinant-protein-structure]( "Yeast Extracts: Improving Expression")
Yeast Extracts: Improving ExpressionYeast extract improves E. coli protein production by over 50%, boosts desired protein attributes 4X, and offers a secure animal-free nutrient source.
-
![Themro Fisher - IgG]( "Maximizing Performance And Quality In Fed-Batch And Perfusion-Based IgG Productions Customer Interview")
Maximizing Performance And Quality In Fed-Batch And Perfusion-Based IgG Productions Customer InterviewFrom lab to production scale: a researcher's firsthand account of what bioreactor scaling and high-density perfusion really demand in practice.
-
![OneTeam™: Setting a New Standard for Biotech Program Visibility]( "OneTeam™: Setting A New Standard for Biotech Program Visibility")
OneTeam™: Setting A New Standard for Biotech Program VisibilityAn on‑demand session showing how integrated governance and real‑time data boost visibility, collaboration, and control in outsourced gene therapy development.
-
Less Risk, More Speed -The New Blueprint For Bioconjugate Development4/15/2026
A fireside chat on how integrated development models reduce risk and accelerate bioconjugate timelines from discovery through GMP manufacturing.
-
Portable Tube Welders Vs Fixed Systems In Biopharma4/14/2026
As manufacturing becomes more flexible and decentralized, sterile connection choices matter more than ever. Explore how portable and fixed tube welders compare and how each supports sterility.
-
Formulating The Future: A Practical Guide To Nucleic Acid Therapeutics4/14/2026
An expert-led webinar exploring nucleic acid therapeutic modalities, delivery systems, formulation challenges, and real-world case studies shaping drug product development.
-
Mississauga Site Wins With Bora Pharmaceuticals4/13/2026
Years of collaboration turned complexity into a seamless, predictable workflow. Shared language, aligned documentation, and trust now speed progress and support faster, more confident execution.
ENTERPRISE SOLUTIONS
-
![GettyImages-1158724314-electorphoresis-hand-filling-cell]( "Scalable Biologics Manufacturing And Antibody Conjugation")
The Syracuse Bio Campus offers U.S.-based mammalian production and bioconjugation, supporting development through commercial manufacturing with regulatory expertise and tailored solutions.
-
![GettyImages-1398569507 regulatory]( "U.S. Pharmaceutical Tariffs (Section 232): Implications & Actions")
New U.S. tariffs are reshaping pharma manufacturing. Early action to assess exposure and pursue onshoring can cut risk, protect margins, and strengthen supply chains.
-
![osd-manufacturing-GettyImages-2145984822]( "Scalable Solutions For High Potent OSD Manufacturing")
High potent oral solid dose manufacturing demands rigorous containment, scalable processes, and regulatory alignment. Learn how closed systems, advanced facilities, and flexible batch strategies support safe development and reliable commercial supply.
-
Single‑site ADC manufacturing integrates antibody production, conjugation, and quality systems to reduce complexity, accelerate timelines, and support scalable clinical‑to‑commercial development.
-
![GettyImages-1013103082 antibodies, cell]( "Pull Your Fill/Finish Line Closer")
By partnering with us, you gain access to our unique, interconnected network, purpose-built to overcome the breakpoints common in traditional manufacturing models.
